reports
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Waga Energy: exclusive negotiations with EQT
This morning, Waga Energy announced it has entered exclusive negotiations with EQT, through its EQT Transition Infrastructure strategy, in the context of a proposed majority block acquisition representing 54.1% of Waga Energy's outstanding shares and 65.9% of voting rights at a price of EUR21.55 pe
Nanobiotix: 1 director
A director at Nanobiotix bought 10,780 shares at 3.415EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ...
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, NYPresenter...
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferie...
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global Healthcare PARIS et CAMBRIDGE, Mass., 28 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : Conférence Jefferies Global HealthcareDate : jeu...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Waga Energy: Hartland is live
This morning, together with the Capital Region District (CRD) of Vancouver, Waga Energy announced it has completed the commissioning and therefore started to produce biomethane in Hartland (Canada). The site has been equipped with a Wagabox capable of producing approximately 100GWh/year of biometha
Nanobiotix Provides First Quarter 2025 Operational and Financial Updat...
Nanobiotix Provides First Quarter 2025 Operational and Financial Update Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial position through an amendment to th...
Nanobiotix fait le point sur sa trésorerie et son activité opérationne...
Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025 Traitement du premier patient dans l’étude CONVERGE, un essai clinique contrôlé randomisé de Phase 2 chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) non résécable de stade 3.Présentation de données à l’ELCC (European Lung Cancer Conference, conférence européenne sur le cancer du poumon) d’une étude de Phase 1 de ré-irradiation avec JNJ-1900 (NBTXR3) dans le CPNPC récurrent locorégional et une étude de Phase 1 avec JNJ-1900 (NBTXR3) en association avec nivoluma...
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’...
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202547 426 85149 535 88349 513 765 À prop...
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2April 30, 202547,426,85149,535,88349,513,765 About NANOBI...
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect...
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm...
Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C...
Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ PARIS and CAMBRIDGE, Mass., 12 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : 3ème conférence investisseurs ann...
- Nicolas David
- Thomas Zlowodzki
EVT EVOTEC SE
ISS ISS A/S
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
PNL POSTNL NV
G24 SCOUT24 AG
NANO NANOBIOTIX SA
ELIS ELIS SA
COFA COFACE SA
IDR INDRA SISTEMAS S.A. CLASS A
SAE SHOP APOTHEKE EUROPE NV
RUI RUBIS SCA
SANT S&T AG
TMV TEAMVIEWER AG
- Nicolas David
- Thomas Zlowodzki
EVT EVOTEC SE
ISS ISS A/S
MTU MANITOU BF SA
ELG ELMOS SEMICONDUCTOR SE
BOSS HUGO BOSS AG
NOEJ NORMA GROUP SE
PNL POSTNL NV
G24 SCOUT24 AG
NANO NANOBIOTIX SA
ELIS ELIS SA
COFA COFACE SA
IDR INDRA SISTEMAS S.A. CLASS A
SAE SHOP APOTHEKE EUROPE NV
RUI RUBIS SCA
SANT S&T AG
TMV TEAMVIEWER AG
- Damien Choplain
- Khouloud Ben Aziza
- Damien Choplain
- Khouloud Ben Aziza
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Waga Energy: new contract in Italy
This morning, Waga Energy announced a new contract in Rosignano Marittimo (Italy) on a site operated by Scapigliato, a public Italian company active in non-hazardous waste management. Planned to be operational in 2027, this site will be equipped with a Wagabox able to produce more than 92GWh/year o
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluat...
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutation...
NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALU...
NANOBIOTIX PRÉSENTE LES RÉSULTATS COMPLETS DE L’ÉTUDE DE PHASE 1 ÉVALUANT JNJ-1900 (NBTXR3) DANS LE CANCER DU PANCREAS Les résultats ont démontré un bon profil de tolérance, une faisabilité d’injection satisfaisante, ainsi que des signaux cliniques encourageants en matière d‘activité antitumorale chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de résécabilité (n=22).La médiane de survie globale est de 23 mois à partir de la date du diagnostic [IC à 95 % ; 17 mois – non atteinte]La médiane de survie sans progression locale est de : 13,3 mois après la fin d...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Waga Energy: post roadshow estimates update
Following Waga Energy's FY results and taking advantage of the roadshow held recently with management, we have updated our model, reviewing our sales and margin assumptions from 2025 onwards. Waga Energy has a unique landfill gas treatment technology (known as cryogenic distillation), already secur
Nanobiotix Announces Presentation of Full Results From Completed Phase...
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.